Do analysts prefer ZYXI or ZJYL?

Zynex currently has a consensus target price of $3.35, suggesting a potential upside of 2,580.00%. Given Zynex's stronger consensus rating and higher probable upside, equities research analysts plainly believe Zynex is more favorable than Jin Medical International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zynex 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Jin Medical International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, ZYXI or ZJYL?

Zynex has higher revenue and earnings than Jin Medical International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zynex $108.20M 0.04 $2.99M -$2.43 N/A Jin Medical International $20.69M 0.74 $1.19M N/A N/A

Does the media favor ZYXI or ZJYL?

In the previous week, Jin Medical International had 2 more articles in the media than Zynex. MarketBeat recorded 3 mentions for Jin Medical International and 1 mentions for Zynex. Jin Medical International's average media sentiment score of 0.96 beat Zynex's score of 0.00 indicating that Jin Medical International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zynex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jin Medical International 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, ICCM or ZYXI?

Zynex has higher revenue and earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IceCure Medical $3.38M 3.65 -$15.06M -$7.21 N/A Zynex $108.20M 0.04 $2.99M -$2.43 N/A

Is ICCM or ZYXI more profitable?

Zynex has a net margin of -68.35% compared to IceCure Medical's net margin of -441.60%. IceCure Medical's return on equity of -211.73% beat Zynex's return on equity. Company Net Margins Return on Equity Return on Assets IceCure Medical -441.60% -211.73% -119.13% Zynex -68.35% -804.30% -36.67%

Does the media favor ICCM or ZYXI?

In the previous week, IceCure Medical had 2 more articles in the media than Zynex. MarketBeat recorded 3 mentions for IceCure Medical and 1 mentions for Zynex. IceCure Medical's average media sentiment score of 0.29 beat Zynex's score of 0.00 indicating that IceCure Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IceCure Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zynex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ZYXI or PFSA?

Zynex presently has a consensus target price of $3.35, suggesting a potential upside of 2,580.00%. Given Zynex's stronger consensus rating and higher possible upside, research analysts clearly believe Zynex is more favorable than Profusa. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zynex 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, ZYXI or PFSA?

Zynex has higher revenue and earnings than Profusa. Zynex is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zynex $108.20M 0.04 $2.99M -$2.43 N/A Profusa $100K 3.82 -$35.82M -$169.72 N/A

Is ZYXI or PFSA more profitable?

Profusa has a net margin of 0.00% compared to Zynex's net margin of -68.35%. Profusa's return on equity of 0.00% beat Zynex's return on equity. Company Net Margins Return on Equity Return on Assets Zynex -68.35% -804.30% -36.67% Profusa N/A N/A -1,348.07%

Which has stronger valuation & earnings, ZYXI or FEMY?

Zynex has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zynex $108.20M 0.04 $2.99M -$2.43 N/A Femasys $2.29M 4.75 -$18.63M -$5.40 N/A

Is ZYXI or FEMY more profitable?

Zynex has a net margin of -68.35% compared to Femasys' net margin of -521.97%. Femasys' return on equity of -258.08% beat Zynex's return on equity. Company Net Margins Return on Equity Return on Assets Zynex -68.35% -804.30% -36.67% Femasys -521.97% -258.08% -73.72%

Do analysts prefer ZYXI or OSRH?

Zynex currently has a consensus target price of $3.35, indicating a potential upside of 2,580.00%. Given Zynex's stronger consensus rating and higher possible upside, equities analysts plainly believe Zynex is more favorable than OSR. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zynex 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, ZYXI or OSRH?

Zynex has higher revenue and earnings than OSR. OSR is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zynex $108.20M 0.04 $2.99M -$2.43 N/A OSR $2.91M 4.37 -$27.06M -$0.33 N/A

Is ZYXI or OSRH more profitable?

Zynex has a net margin of -68.35% compared to OSR's net margin of -363.26%. OSR's return on equity of -7.24% beat Zynex's return on equity. Company Net Margins Return on Equity Return on Assets Zynex -68.35% -804.30% -36.67% OSR -363.26% -7.24% -5.41%

Zynex (ZYXI) Competitors

$0.12 0.00 (0.00%)

As of 07/13/2026

Compare

ZYXI vs. ZJYL, ICCM, PFSA, FEMY, and OSRH

Should you buy Zynex stock or one of its competitors? MarketBeat compares Zynex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zynex include Jin Medical International (ZJYL), IceCure Medical (ICCM), Profusa (PFSA), Femasys (FEMY), and OSR (OSRH). These companies are all part of the "medical equipment" industry.

How does Zynex compare to Jin Medical International?

Zynex (NASDAQ:ZYXI) and Jin Medical International (NASDAQ:ZJYL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

In the previous week, Jin Medical International had 2 more articles in the media than Zynex. MarketBeat recorded 3 mentions for Jin Medical International and 1 mentions for Zynex. Jin Medical International's average media sentiment score of 0.96 beat Zynex's score of 0.00 indicating that Jin Medical International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zynex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jin Medical International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zynex has higher revenue and earnings than Jin Medical International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zynex	$108.20M	0.04	$2.99M	-$2.43	N/A
Jin Medical International	$20.69M	0.74	$1.19M	N/A	N/A

Jin Medical International has a net margin of 0.00% compared to Zynex's net margin of -68.35%. Jin Medical International's return on equity of 0.00% beat Zynex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zynex	-68.35%	-804.30%	-36.67%
Jin Medical International	N/A	N/A	N/A

Zynex currently has a consensus target price of $3.35, suggesting a potential upside of 2,580.00%. Given Zynex's stronger consensus rating and higher probable upside, equities research analysts plainly believe Zynex is more favorable than Jin Medical International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zynex	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Jin Medical International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Zynex has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Jin Medical International has a beta of 7.34, suggesting that its share price is 634% more volatile than the broader market.

29.7% of Zynex shares are held by institutional investors. 49.3% of Zynex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Zynex and Jin Medical International tied by winning 7 of the 14 factors compared between the two stocks.

How does Zynex compare to IceCure Medical?

IceCure Medical (NASDAQ:ICCM) and Zynex (NASDAQ:ZYXI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

IceCure Medical has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market. Comparatively, Zynex has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market.

Zynex has a net margin of -68.35% compared to IceCure Medical's net margin of -441.60%. IceCure Medical's return on equity of -211.73% beat Zynex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-441.60%	-211.73%	-119.13%
Zynex	-68.35%	-804.30%	-36.67%

0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 29.7% of Zynex shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by insiders. Comparatively, 49.3% of Zynex shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Zynex has higher revenue and earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.38M	3.65	-$15.06M	-$7.21	N/A
Zynex	$108.20M	0.04	$2.99M	-$2.43	N/A

In the previous week, IceCure Medical had 2 more articles in the media than Zynex. MarketBeat recorded 3 mentions for IceCure Medical and 1 mentions for Zynex. IceCure Medical's average media sentiment score of 0.29 beat Zynex's score of 0.00 indicating that IceCure Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IceCure Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zynex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IceCure Medical currently has a consensus price target of $62.70, suggesting a potential upside of 1,641.67%. Zynex has a consensus price target of $3.35, suggesting a potential upside of 2,580.00%. Given Zynex's higher possible upside, analysts clearly believe Zynex is more favorable than IceCure Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Zynex	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Zynex beats IceCure Medical on 9 of the 15 factors compared between the two stocks.

How does Zynex compare to Profusa?

Zynex (NASDAQ:ZYXI) and Profusa (NASDAQ:PFSA) are both small-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

In the previous week, Profusa had 1 more articles in the media than Zynex. MarketBeat recorded 2 mentions for Profusa and 1 mentions for Zynex. Profusa's average media sentiment score of 0.38 beat Zynex's score of 0.00 indicating that Profusa is being referred to more favorably in the news media.

Company	Overall Sentiment
Zynex	Neutral
Profusa	Neutral

Zynex has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market. Comparatively, Profusa has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market.

Profusa has a net margin of 0.00% compared to Zynex's net margin of -68.35%. Profusa's return on equity of 0.00% beat Zynex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zynex	-68.35%	-804.30%	-36.67%
Profusa	N/A	N/A	-1,348.07%

Zynex presently has a consensus target price of $3.35, suggesting a potential upside of 2,580.00%. Given Zynex's stronger consensus rating and higher possible upside, research analysts clearly believe Zynex is more favorable than Profusa.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zynex	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

29.7% of Zynex shares are owned by institutional investors. Comparatively, 9.8% of Profusa shares are owned by institutional investors. 49.3% of Zynex shares are owned by company insiders. Comparatively, 0.8% of Profusa shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Zynex has higher revenue and earnings than Profusa. Zynex is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zynex	$108.20M	0.04	$2.99M	-$2.43	N/A
Profusa	$100K	3.82	-$35.82M	-$169.72	N/A

Summary

Zynex beats Profusa on 10 of the 15 factors compared between the two stocks.

How does Zynex compare to Femasys?

Zynex (NASDAQ:ZYXI) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Zynex has a net margin of -68.35% compared to Femasys' net margin of -521.97%. Femasys' return on equity of -258.08% beat Zynex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zynex	-68.35%	-804.30%	-36.67%
Femasys	-521.97%	-258.08%	-73.72%

Zynex has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zynex	$108.20M	0.04	$2.99M	-$2.43	N/A
Femasys	$2.29M	4.75	-$18.63M	-$5.40	N/A

29.7% of Zynex shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 49.3% of Zynex shares are held by company insiders. Comparatively, 7.8% of Femasys shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Zynex has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Femasys has a beta of -2.13, suggesting that its share price is 313% less volatile than the broader market.

Zynex presently has a consensus price target of $3.35, indicating a potential upside of 2,580.00%. Femasys has a consensus price target of $106.67, indicating a potential upside of 2,862.96%. Given Femasys' stronger consensus rating and higher probable upside, analysts clearly believe Femasys is more favorable than Zynex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zynex	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Zynex and Zynex both had 1 articles in the media. Femasys' average media sentiment score of 1.87 beat Zynex's score of 0.00 indicating that Femasys is being referred to more favorably in the news media.

Company	Overall Sentiment
Zynex	Neutral
Femasys	Very Positive

Summary

Zynex and Femasys tied by winning 7 of the 14 factors compared between the two stocks.

How does Zynex compare to OSR?

Zynex (NASDAQ:ZYXI) and OSR (NASDAQ:OSRH) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

In the previous week, Zynex and Zynex both had 1 articles in the media. OSR's average media sentiment score of 0.94 beat Zynex's score of 0.00 indicating that OSR is being referred to more favorably in the news media.

Company	Overall Sentiment
Zynex	Neutral
OSR	Positive

Zynex has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, OSR has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

Zynex has higher revenue and earnings than OSR. OSR is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zynex	$108.20M	0.04	$2.99M	-$2.43	N/A
OSR	$2.91M	4.37	-$27.06M	-$0.33	N/A

Zynex has a net margin of -68.35% compared to OSR's net margin of -363.26%. OSR's return on equity of -7.24% beat Zynex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zynex	-68.35%	-804.30%	-36.67%
OSR	-363.26%	-7.24%	-5.41%

29.7% of Zynex shares are held by institutional investors. Comparatively, 55.3% of OSR shares are held by institutional investors. 49.3% of Zynex shares are held by insiders. Comparatively, 36.8% of OSR shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Zynex currently has a consensus target price of $3.35, indicating a potential upside of 2,580.00%. Given Zynex's stronger consensus rating and higher possible upside, equities analysts plainly believe Zynex is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zynex	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Zynex beats OSR on 8 of the 14 factors compared between the two stocks.

Get Zynex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZYXI vs. The Competition

Export

Metric	Zynex	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.80M	$8.16B	$6.72B	$12.54B
Dividend Yield	N/A	2.54%	2.68%	8.00%
P/E Ratio	-0.05	15.65	27.04	24.40
Price / Sales	0.04	7.04	584.12	117.53
Price / Cash	0.51	18.40	29.22	49.36
Price / Book	0.11	3.56	10.81	6.34
Net Income	$2.99M	$228.19M	$3.59B	$331.02M
7 Day Performance	N/A	-3.20%	-2.24%	-1.09%
1 Month Performance	N/A	-1.55%	3.12%	-0.49%
1 Year Performance	-94.08%	-3.53%	26.30%	19.90%

Zynex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZYXI Zynex	2.2065 of 5 stars	$0.13 flat	$3.35 +2,580.0%	N/A	$3.80M	$108.20M	N/A	770	News Coverage
ZJYL Jin Medical International	1.1065 of 5 stars	$1.87 -5.6%	N/A	-85.5%	$14.64M	$20.69M	N/A	245	Short Interest Decrease Gap Up
ICCM IceCure Medical	2.7608 of 5 stars	$4.15 -10.0%	$62.70 +1,410.8%	-88.7%	$14.24M	$3.38M	N/A	60	Analyst Upgrade Short Interest Increase
PFSA Profusa	0.1124 of 5 stars	$2.77 -2.9%	N/A	N/A	$12.89M	$100K	N/A	2	Short Interest Increase Gap Down
FEMY Femasys	2.1016 of 5 stars	$3.86 -5.4%	$106.67 +2,663.4%	-81.2%	$11.66M	$2.29M	N/A	30	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZYXI) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zynex (ZYXI) Competitors

ZYXI vs. ZJYL, ICCM, PFSA, FEMY, and OSRH

How does Zynex compare to Jin Medical International?

Summary

How does Zynex compare to IceCure Medical?

Summary

How does Zynex compare to Profusa?

Summary

How does Zynex compare to Femasys?

Summary

How does Zynex compare to OSR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYXI vs. The Competition

Zynex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zynex (ZYXI) Competitors

ZYXI vs. ZJYL, ICCM, PFSA, FEMY, and OSRH

How does Zynex compare to Jin Medical International?

Does the media favor ZYXI or ZJYL?

Which has better earnings and valuation, ZYXI or ZJYL?

Is ZYXI or ZJYL more profitable?

Do analysts prefer ZYXI or ZJYL?

Which has more volatility and risk, ZYXI or ZJYL?

Do insiders & institutionals hold more shares of ZYXI or ZJYL?

Summary

How does Zynex compare to IceCure Medical?

Which has more risk and volatility, ICCM or ZYXI?

Is ICCM or ZYXI more profitable?

Do insiders and institutionals hold more shares of ICCM or ZYXI?

Which has better valuation & earnings, ICCM or ZYXI?

Does the media favor ICCM or ZYXI?

Do analysts rate ICCM or ZYXI?

Summary

How does Zynex compare to Profusa?

Does the media favor ZYXI or PFSA?

Which has more risk & volatility, ZYXI or PFSA?

Is ZYXI or PFSA more profitable?

Do analysts recommend ZYXI or PFSA?

Do institutionals & insiders hold more shares of ZYXI or PFSA?

Which has preferable earnings and valuation, ZYXI or PFSA?

Summary

How does Zynex compare to Femasys?

Is ZYXI or FEMY more profitable?

Which has stronger valuation & earnings, ZYXI or FEMY?

Do insiders & institutionals hold more shares of ZYXI or FEMY?

Which has more volatility and risk, ZYXI or FEMY?

Do analysts prefer ZYXI or FEMY?

Does the media refer more to ZYXI or FEMY?

Summary

How does Zynex compare to OSR?

Does the media refer more to ZYXI or OSRH?

Which has more risk & volatility, ZYXI or OSRH?

Which has higher valuation and earnings, ZYXI or OSRH?

Is ZYXI or OSRH more profitable?

Do insiders and institutionals hold more shares of ZYXI or OSRH?

Do analysts prefer ZYXI or OSRH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYXI vs. The Competition

Zynex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools